logo-loader

Lisata Therapeutics completes enrollment in Phase 2a BOLSTER trial for certepetide in bile duct cancer

Published: 14:26 16 Jul 2024 BST

Lisata Therapeutics Inc -

Lisata Therapeutics Inc (NASDAQ:LSTA) said it has completed enrollment in its Phase 2a BOLSTER trial for certepetide, a promising investigational treatment for first-line cholangiocarcinoma (CCA).

The BOLSTER trial, a Phase 2a double-blind, placebo-controlled study conducted across multiple centers in the United States, evaluates certepetide in combination with standard-of-care versus standard-of-care alone for patients with first-line CCA.

In a statement, Lisata said it has expanded the BOLSTER trial to include an arm specifically assessing certepetide's efficacy in second-line treatment in response to the urgent demand to enhance treatment outcomes in second-line CCA.

The company anticipates enrolling the first patient in this arm by the fourth quarter of 2024.

Kristen Buck, Lisata’s chief medical officer, told shareholders that completing enrollment in the first-line CCA cohort of the BOLSTER trial is a “significant accomplishment” for the company and a major step forward in the development of certepetide for CCA.

“This achievement underscores the dedication and enthusiasm of everyone involved in supporting the study, both internally and externally, as well as the promise of certepetide as a first-line treatment option for CCA,” Buck said in a statement.

Top-line data from the trial is anticipated by mid-2025.

Arrow Exploration CEO on Icaco success, record production and next drilling...

Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) CEO Marshall Abbott talked with Proactive's Stephen Gunnion about the company's latest drilling success at Icaco in Colombia, where the IC-HZ9 well has exceeded production expectations and helped lift corporate output above 7,000 barrels of...

3 hours, 34 minutes ago